Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

9.745 -0.045 (-0.46%)
Streaming Delayed Price Updated: 12:42 PM EDT, Sep 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
ARS Pharmaceuticals' EpiPen Alternative Delayed US Approval - Two Analysts Offer Differing Views
On Tuesday, The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic... 
Via Benzinga
What's Going On With ARS Pharmaceuticals Stock Today?
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares are trading higher Thursday. The move marks a rebound in the stock following a recent drop in price. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Gold Moves Higher; Fed Leaves Key Overnight Interest Rate Unchanged
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 200 points on Wednesday. The Dow traded up 0.59% to 34,720.69 while the NASDAQ fell 0.07% to 13,668.37. The S&P 500... 
Via Benzinga
Topics Economy Stocks
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday
The company received a Complete Response Letter from the FDA regarding its lead therapy. 
Via The Motley Fool
Nasdaq Turns Lower; Cambridge Bancorp Shares Surge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Wednesday. The Dow traded up 0.56% to 34,711.50 while the NASDAQ fell 0.17% to 13,654.54. The S&P 500 also... 
Via Benzinga
Topics Stocks
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023
 
Via Benzinga
Analyst Expectations for ARS Pharmaceuticals's Future
 
Via Benzinga
Dow Gains 150 Points; General Mills Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 150 points on Tuesday. The Dow traded up 0.47% to 34,680.84 while the NASDAQ rose 0.26% to 13,713.13. The S&P 500 also rose,... 
Via Benzinga
Topics Stocks
Elon Musk-Backed Neuralink Starts Participant Enrollment For Paralysis, Eli Lilly Cracks Down on Counterfeit Weight Loss Drugs, Meta Looks to Capitalize on India's In-App Payment Surge: Today's Top Stories
Benzinga 
Via Benzinga
FDA Rejects EpiPen Alternative - ARS Pharmaceuticals' Allergic Reaction Nasal Spray
The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday. 
Via Benzinga
Instacart, ARS Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
Additional Time Needed for Labeling and Post-Marketing Requirements Discussions; PDUFA Date Set for September 19, 2023 
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Nasdaq Down 100 Points; Crude Oil Drops Over 1%
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Friday. The Dow traded down 0.43% to 33,164.71 while the NASDAQ fell 0.82% to 12,227.60. The... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Dow Turns Lower; Getaround Shares Jump
U.S. stocks traded lower midway through trading, with the Dow Jones turning lower on Friday. The Dow traded down 0.25% to 33,226.13 while the NASDAQ fell 0.45% to 12,271.22. The S&P 500, also fell,... 
Via Benzinga
Arlo Technologies, Array Technologies, AirSculpt Technologies And Other Big Stocks Moving Higher On Friday
U.S. stocks traded slightly lower, with the Dow Jones dropping around 15 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16,... 
Via Benzinga
Why ARS Pharmaceuticals Stock Is Soaring Today
The FDA's Pulmonary-Allergy Drug Advisory Committee voted 16-6 in favor of ARS Pharmaceuticals Inc's (NASDAQ: SPRY) neffy in treating severe allergic reactions for adults (and 16-5 for  
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.